Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30339144 | 0.85 | RAB9A (0.46) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL10129490 | 0.81 | SSTR4 (0.48) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL16595330 | 0.80 | PTGS1 (0.55) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL9796679 | 0.78 | SSTR4 (0.46) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL23562883 | 0.78 | RAB9A (0.45) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL3313092 | 0.75 | RAB9A (0.65) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL18517250 | 0.75 | NPC1 (0.48) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL29320765 | 0.75 | SSTR4 (0.47) | RAB9ANPC1PTGS1PTGS2KDM4E | |
| SCHEMBL20208548 | 0.75 | SCN5A (0.68) | RAB9ANPC1SCN5AKDM4ESMN1; SMN2 | |
| SCHEMBL12056714 | 0.73 | SCN5A (0.54) | RAB9ANPC1PTGS1PTGS2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | claimed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2231660-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | Wyeth LLC (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009086123-A1 | IMIDAZO [1,2-A] PYRIDINE COMPOUNDS | WYETH (US) | 2009-07-09 | — | — | WO | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024175804-A1 | NUCLEAR TRANSPORT MODULATORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-08-29 | — | — | WO | disclosed |
| US-11993601-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV | 2024-05-28 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| EP-0238070-B1 | Sulfonylurea compounds, their production and herbicidal use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-12-29 | — | — | EP | disclosed |
| US-5017212-A | For rice paddies | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-21 | — | — | US | disclosed |
| EP-0238070-A2 | Sulfonylurea compounds, their production and herbicidal use | Takeda Chemical Industries, Ltd. (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | RAB9A 1445/4885NPC1 123/4885PTGS1 1980/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | RAB9A 1657/4885NPC1 161/4885PTGS1 1930/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | RAB9A 1445/4885NPC1 123/4885PTGS1 1980/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | RAB9A 547/4885NPC1 416/4885PTGS1 211/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | RAB9A 1445/4885NPC1 123/4885PTGS1 1980/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | RAB9A 1917/4885NPC1 174/4885PTGS1 1975/4885 |
| US-11993601-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | RAB9A 994/4885NPC1 826/4885PTGS1 940/4885 |
| US-20240327410-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | RAB9A 994/4885NPC1 826/4885PTGS1 940/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | RAB9A 1917/4885NPC1 174/4885PTGS1 1975/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | RAB9A 1445/4885NPC1 123/4885PTGS1 1980/4885 |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | RAB9A 2844/4885NPC1 241/4885PTGS1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.